Skip to content

Skye Bioscience, Inc.

SKYE

CIK 0001516551

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$53.99M
−110.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.36
−93.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$26.52M
Q1 May 2026
Cash
$8.15M
Q1 May 2026
Total Debt
$116.7K
Q1 May 2026
Shares Outstanding
35.14M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings